COCP - コクリスタル・ファ―マ (Cocrystal Pharma Inc.) コクリスタル・ファ―マ

 COCPのチャート


 COCPの企業情報

symbol COCP
会社名 Cocrystal Pharma Inc (コクリスタル・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Cocrystal Pharma Inc. is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.   コクリスタル・ファ―マは米国の医薬品企業。主にヒトのウィルス性疾患の治療薬の開発に従事する。ウィルスの複製機能を阻害する抗ウィルス治療薬で、RNAポリメラ―ゼ酵素、ヘリカ―ゼ酵素、C型肝炎のNS5Aたんぱく質、インフルエンザウィルスやノロウィルスのRNAポリメラ―ゼを含む。同社は薬物レベルでの酵素相互作用に焦点を当てる。本社はジョ―ジア州タッカ―。   
本社所在地 1860 Montreal Road Tucker GA 30084 USA
代表者氏名 Raymond F. Schinazi レイモンドF.シナジー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 425-398-7178
設立年月日 39052
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 10人
url https://www.cocrystalpharma.com/
nasdaq_url https://www.nasdaq.com/symbol/cocp
adr_tso
EBITDA EBITDA(百万ドル) -8.06300
終値(lastsale) 2.725
時価総額(marketcap) 81540382.1
時価総額 時価総額(百万ドル) 81.98923
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 75.14823
当期純利益 当期純利益(百万ドル) 0.04100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cocrystal Pharma Inc revenues was not reported. Net loss decreased 18% to $2.9M. Lower net loss reflects Research and development decrease of 40% to $2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.11.

 COCPのテクニカル分析


 COCPのニュース

   Why Cocrystal Pharma, Precision BioScience Are Trading Higher Today  2021/01/19 17:18:23 Benzinga
Cocrystal Pharma (NASDAQ: COCP ) shares are trading higher after the company announced … Full story available on Benzinga.com
   Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference  2021/01/05 08:00:00 Benzinga
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company"), a clinical-stage biotechnology …
   72 Biggest Movers From Wednesday  2020/11/27 10:01:25 Benzinga
Gainers AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) shares jumped 104% to close at $7.14 on Wednesday after the company issued strong sales forecast for FY20. Newborn Acquisition Corp. (NASDAQ: NBAC ) jumped 86.2% to close at $22.27 after gaining around 8% on Tuesday. Mmtec, Inc. (NASDAQ: MTC ) jumped 67.5% to close at $2.01 on Wednesday after climbing over 11% on Tuesday. Future FinTech Group Inc. (NASDAQ: FTFT ) gained 40.2% to close at $3.00. Slack Technologies, Inc. (NYSE: WORK ) climbed 37.6% to close at $40.70 following reports indicating Salesforce has held M&A talks with the company. Fisker Inc. (NYSE: FSR ) rose 35.3% to close at $21.61 after Citigroup initiated coverage on the stock with a Buy rating and a price target of $26 per share. Appian Corporation (NASDAQ: APPN ) jumped 31.7% to close at $174.90. Renalytix AI PLC (NASDAQ: RNLX ) jumped 31.7% to close at $14.08 after the company's Kantaro Biosciences joint venture received FDA Emergency Use Authorization for its COVID-SeroKlir antibody test kit.
   50 Stocks Moving In Wednesday's Mid-Day Session - Stocks News Feed  2020/11/25 18:37:32 Stocks News Feed
Gainers AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC) shares climbed 99.7% to $6.99 after the company issued strong sales forecast for FY20. Mmtec, Inc. (NASDAQ: MTC) climbed 82.2% to $2.20 after climbing over 11% on Tuesday. Newborn Acquisition Corp. (NASDAQ: NBAC) climbed 56.4% to $18.70 after gaining around 8% on Tuesday. Cocrystal Pharma,… Read More »50 Stocks Moving In Wednesday’s Mid-Day Session
   Cocrystal Pharma: 8 Things for COCP Investors to Know About the Biotech Stock  2020/11/25 14:31:51 InvestorPlace
Cocrystal Pharma (COCP) is on the move Wednesday even with there being a lack of news concerning the pharmaceutical company.
   50 Stocks Moving In Wednesday's Mid-Day Session - Stocks News Feed  2020/11/25 18:37:32 Stocks News Feed
Gainers AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC) shares climbed 99.7% to $6.99 after the company issued strong sales forecast for FY20. Mmtec, Inc. (NASDAQ: MTC) climbed 82.2% to $2.20 after climbing over 11% on Tuesday. Newborn Acquisition Corp. (NASDAQ: NBAC) climbed 56.4% to $18.70 after gaining around 8% on Tuesday. Cocrystal Pharma,… Read More »50 Stocks Moving In Wednesday’s Mid-Day Session
   Cocrystal Pharma: 8 Things for COCP Investors to Know About the Biotech Stock  2020/11/25 14:31:51 InvestorPlace
Cocrystal Pharma (COCP) is on the move Wednesday even with there being a lack of news concerning the pharmaceutical company.
   Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference  2020/11/06 13:00:00 GlobeNewswire
– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST – BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) --…
   Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference  2020/09/08 12:00:00 GlobeNewswire
– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT – BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE)…
   Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs  2020/08/06 12:05:00 GlobeNewswire
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop…
   How The COVID-19 Outbreak Is Benefiting Biotech Investors  2020/03/02 19:27:13 Benzinga Feeds
It took a viral outbreak to stall the market's bull run. The U.S. market is in correction territory, with two of the three major averages having pulled back more than 10% from their recent peaks. The across-the-board sell-off has left many investors with evaporating gains and balance sheets dipping into the red. The biotech sector has weathered the COVID-19 impact relatively better than the broader market. Source: Trading View Biotech stocks inherently are defensive bets that are largely immune to changes in economic conditions. Stocks levered to COVID-19 — and specifically those developing therapies or vaccines targeting the virus — have seen meteoric gains. Some of these stocks have netted returns higher than Tesla Inc (NASDAQ: TSLA ) shares, which have been on a terrific run and are up 62% year-to-date following a mid-February pullback along with the broader market. Biotech, Diagnostic Stocks Moving On COVID-19 Developments Therapies Gilead Sciences, Inc. (NASDAQ: GILD ): Gilead has initiated two Phase 3 studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.
   Nanocap Biotech Stock Rips 180% Higher On Coronavirus Drug Licensing  2020/02/24 16:20:21 Benzinga
Cocrystal Pharma Inc (NASDAQ: COCP ) shares are skyrocketing Monday following a licensing agreement the company reached with the Kansas State University Research Foundation. Cocrystal said the agreement with KSURF gives it an exclusive, royalty-bearing right and license to certain antiviral compounds for the treatment of norovirus and coronavirus … Full story available on Benzinga.com
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut  2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.

 関連キーワード  (医薬品 米国株 コクリスタル・ファ―マ COCP Cocrystal Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)